Takeda Pharmaceutical Company Ltd
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Phase 3
Not yet recruiting
- Conditions
- Multiple MyelomaSecondary Immunodeficiency
- Interventions
- Biological: IGI, 10%
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 183
- Registration Number
- NCT06980480
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Phase 3
Not yet recruiting
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Placebo to match zasocitinibDrug: Placebo to match deucravacitinib
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT06973291
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 13
- Registration Number
- NCT06973304
- Locations
- π¨π³
Beijing Tsinghua Changgung Hospital, Changping, Beijing, China
π¨π³Peking Union Medical College Hospital, Dongcheng, Beijing, China
π¨π³The General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 347
- Registration Number
- NCT06963827
Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA
- Conditions
- Primary Immunodeficiency Diseases (PIDD)
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Takeda
- Registration Number
- NCT06955793
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT06952699
- Locations
- πΊπΈ
Takeda Site 14, Redwood City, California, United States
πΊπΈTakeda Site 5, Cincinnati, Ohio, United States
πΊπΈTakeda Site 10, Santa Ana, California, United States
A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Phase 3
Not yet recruiting
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06948318
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Device: SC Investigational Needle Sets
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 64
- Registration Number
- NCT06935266
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Study of TAK-881 and HyQvia in Healthy Adults
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT06895967
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease
Recruiting
- Conditions
- Dengue Fever
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 70000
- Registration Number
- NCT06843226
- Locations
- πΉπ
Nakhon Phanom hospital, Mueang Nakhon Phanom, Nakhon Phanom, Thailand
πΉπPhra Nakhon Si Ayutthaya Hospital, Mueang Phra Nakhon Si Ayutthaya, Phra Nakhon Si Ayutthaya, Thailand
Β© Copyright 2025. All Rights Reserved by MedPath